|
RU2086544C1
(ru)
|
1991-06-13 |
1997-08-10 |
Хоффманн-Ля Рош АГ |
Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
|
|
US5820915A
(en)
|
1996-06-27 |
1998-10-13 |
Bioavailability Systems, L.L.C. |
Method for the preparation of a first-pass effective citrus-derived substance and product thereof
|
|
US6124477A
(en)
|
1996-06-27 |
2000-09-26 |
Bioavailability Systems, Llc |
Anti-first-pass effect compounds
|
|
US5990154A
(en)
|
1997-05-30 |
1999-11-23 |
Bioavailability Systems, L.L.C. |
Anti-first-pass effect compounds and citrus extract
|
|
US6063809A
(en)
|
1997-08-26 |
2000-05-16 |
Bioavailability Systems, Llc |
Anti-first-pass effect compounds
|
|
US6248776B1
(en)
|
1997-08-26 |
2001-06-19 |
Bioavailability Systems, L.L.C. |
Anti-first-pass effect compounds
|
|
US20040058982A1
(en)
|
1999-02-17 |
2004-03-25 |
Bioavailability System, Llc |
Pharmaceutical compositions
|
|
US5993887A
(en)
|
1998-06-29 |
1999-11-30 |
Bioavailability Systems, L.L.C. |
Safe citrus juice and process for preparation
|
|
WO2004037827A1
(en)
|
2000-10-20 |
2004-05-06 |
Bioavailability Systems, Llc |
Synthesis of spiro ortho esters, spiro ortho carbonates, and intermediates
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
EP1732891A4
(en)
|
2004-03-11 |
2009-05-06 |
Sequoia Pharmaceuticals Inc |
RESISTANT PREVENTIVE INHIBITORS FOR RETROVIRAL PROTEASES
|
|
EP2422781A1
(en)
|
2004-05-07 |
2012-02-29 |
Sequoia Pharmaceuticals, Inc. |
Resistance-repellent retroviral protease inhibitors
|
|
US20090281114A1
(en)
|
2008-05-08 |
2009-11-12 |
Fabre-Kramer Pharmaceuticals, Inc. |
Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction
|
|
AR071717A1
(es)
|
2008-05-13 |
2010-07-07 |
Array Biopharma Inc |
Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
|
|
KR20180084153A
(ko)
|
2011-06-10 |
2018-07-24 |
메르크 파텐트 게엠베하 |
Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
|
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
|
TWI599356B
(zh)
|
2012-09-26 |
2017-09-21 |
安羅格製藥有限責任公司 |
抑制突變型ｃ－ｋｉｔ的方法
|
|
ES2750523T3
(es)
|
2012-12-18 |
2020-03-26 |
Almirall Sa |
Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
|
|
US9458124B2
(en)
|
2013-02-06 |
2016-10-04 |
Wayne State University |
Substituted pyran derivatives
|
|
KR20150130389A
(ko)
|
2013-03-13 |
2015-11-23 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법
|
|
WO2015108940A2
(en)
|
2014-01-14 |
2015-07-23 |
The Trustees Of The University Of Pennsylvania |
Tailored combinatorial epigenetic therapies for p53 gain-of-function tumors
|
|
US20170119769A1
(en)
|
2014-06-10 |
2017-05-04 |
The Trustees Of The University Of Pennsylvania |
Scaffolds for inhibitors of menin-mll interactions
|
|
WO2016025635A2
(en)
*
|
2014-08-13 |
2016-02-18 |
Epizyme, Inc. |
Combination therapy for treating cancer
|
|
CN105732636B
(zh)
|
2014-12-30 |
2020-04-21 |
广东东阳光药业有限公司 |
杂芳化合物及其在药物中的应用
|
|
WO2016197027A1
(en)
|
2015-06-04 |
2016-12-08 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with mll proteins
|
|
AU2016378579A1
(en)
|
2015-12-22 |
2018-06-14 |
Vitae Pharmaceuticals, Inc. |
Inhibitors of the menin-MLL interaction
|
|
EP4643952A3
(en)
|
2016-01-26 |
2026-01-14 |
Memorial Sloan Kettering Cancer Center |
Targeting chromatin regulators for inhibiting leukemogenic gene expression in npm1
|
|
CN109640987B
(zh)
|
2016-03-16 |
2022-12-02 |
库拉肿瘤学公司 |
Menin-mll的桥联双环抑制剂及使用方法
|
|
WO2017192543A1
(en)
|
2016-05-02 |
2017-11-09 |
Regents Of The University Of Michigan |
Piperidines as menin inhibitors
|
|
EP3454862B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
EP3805215A1
(en)
*
|
2016-06-10 |
2021-04-14 |
Vitae Pharmaceuticals, LLC |
Inhibitors of the menin-mll interaction
|
|
US10899758B2
(en)
|
2016-09-16 |
2021-01-26 |
Vitae Pharmaceuticals, Llc |
Inhibitors of the menin-MLL interaction
|
|
CN110691779B
(zh)
|
2017-03-24 |
2023-10-10 |
库拉肿瘤学公司 |
治疗血液系统恶性肿瘤和尤因肉瘤的方法
|
|
KR20200101389A
(ko)
|
2017-12-20 |
2020-08-27 |
얀센 파마슈티카 엔.브이. |
메닌-mll 상호작용의 엑소-아자 스피로 억제제
|
|
EP3740491A1
(en)
|
2018-01-18 |
2020-11-25 |
Array Biopharma, Inc. |
Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
|
|
JP2021519785A
(ja)
|
2018-03-30 |
2021-08-12 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
共有結合性メニン阻害剤としてのピペリジン化合物
|
|
AU2019337547A1
(en)
|
2018-09-13 |
2021-03-18 |
Merck Sharp & Dohme Llc |
Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
|
|
EP3856173A4
(en)
|
2018-09-26 |
2022-07-06 |
Kura Oncology, Inc. |
TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH MENIN INHIBITORS
|
|
EP3906026A4
(en)
|
2018-12-31 |
2022-10-19 |
Biomea Fusion, LLC |
IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
|
|
MX2022012471A
(es)
|
2020-04-07 |
2022-11-30 |
Syndax Pharmaceuticals Inc |
Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
|
|
AU2022271791A1
(en)
|
2021-05-12 |
2024-01-04 |
Board Of Regents, The University Of Texas System |
Combinations for treatment of cancer
|
|
TW202311262A
(zh)
|
2021-05-14 |
2023-03-16 |
美商錫達斯醫藥股份有限公司 |
Menin-mll交互作用之抑制劑
|
|
AU2022325861A1
(en)
|
2021-08-11 |
2024-02-29 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
|
CN118234497A
(zh)
|
2021-12-15 |
2024-06-21 |
丹娜-法伯癌症研究所 |
通过破坏menin-mll表观遗传复合体靶向治疗胃肠道间质瘤(gist)
|
|
TW202525797A
(zh)
|
2023-08-28 |
2025-07-01 |
美商錫達斯醫藥股份有限公司 |
作為ｍｅｎｉｎ－ｍｌｌ交互作用之抑制劑的芳基醚類似物
|